Macrocyclic Peptides Draw Wave of Institutional Capital in 2026 as Big Pharma Targets "Undruggable" Biology

Key takeaways

• Syneron Bio (Beijing) closed a $150 million Series B in March 2026, bringing its total raised to approximately $250 million and drawing sovereign wealth and strategic pharma investors.
• In February 2026, Novartis committed up to $1.8 billion to Unnatural Products (UNP) to access AI-guided macrocyclic peptides for cardiovascular disease.
• UNP has separately partnered with Merck, argenx and BridgeBio, building a multi-partner model that is becoming characteristic of the macrocycle platform sector.
• AstraZeneca, which holds an equity stake in Syneron, signed a collaboration potentially worth up to $3.4 billion in milestones in 2025 — one of the largest platform-stage peptide deals recorded.
• The macrocyclic peptide modality occupies structural middle ground between small molecules and biologics, offering oral bioavailability potential that linear peptides cannot easily achieve.

What macrocyclic peptides are, and why they matter

A macrocyclic peptide is a peptide whose amino-acid chain is joined head-to-tail — or bridged internally — to form a ring structure. That cyclic backbone confers conformational rigidity, which reduces the entropic cost of binding to a target protein and can allow the molecule to engage surfaces that are too large and flat for conventional small molecules but too inaccessible for injectable biologics such as monoclonal antibodies.

Small molecules are cell-permeable but often lack selectivity; biologics are highly specific but cell-impermeable. Macrocycles occupy a structural middle ground: larger and more precisely shaped than a typical small molecule, enabling them to target complex protein surfaces, yet stable enough to function in vivo. The class is sometimes described in industry shorthand as "goldilocks" molecules for this reason.

The cyclic backbone architecture confers conformational rigidity that reduces the entropic cost of target binding, while chemical modifications such as N-methylation of amide bonds can enable membrane permeability and oral bioavailability despite molecular weights that exceed standard medicinal chemistry guidelines.

The practical implication is access to so-called undruggable targets — protein–protein interactions, transcription factors and intracellular signalling nodes for which no approved small molecule or biologic exists. It is this promise that is drawing institutional capital at a scale the peptide modality has not previously seen.

Syneron Bio: $150 million Series B closes

On 31 March 2026, Beijing-based Syneron Bio announced the successful closing of its Series B financing, positioning itself as a leader in intelligent platform-driven macrocyclic peptide drug discovery.

The round was led by an unnamed international life sciences fund, along with Decheng Capital and CDH VGC. Additional participants included a wholly owned subsidiary of the Abu Dhabi Investment Authority, True Light Capital, Qiming Venture Partners and BioTrack, as well as existing investors including AstraZeneca, LAV, Sinovation Capital, 5Y Capital and others.

The presence of sovereign wealth capital alongside strategic pharma investors signals a level of institutional confidence unusual for a company with no clinical-stage asset. The financing matters less as a cash event in isolation, and more as a signal that Syneron is being underwritten by a rare mix of blue-chip biotech venture capital, strategic pharma, big tech capital, and sovereign-linked money around a still-early macrocyclic peptide platform story.

The company utilises its proprietary Synova™ platform — an intelligent, high-throughput discovery platform — to design, screen, and optimise peptide drugs to address significant unmet medical needs, building a pipeline focused on oncology and chronic diseases including autoimmune and metabolic disorders. Synova combines AI, data science, and high-throughput screening to improve the efficiency and success rate of identifying macrocyclic peptides that combine the specificity of biologics with the drug-like properties of small molecules.

The two disclosed preclinical candidates both sit in oncology. SYNB021225 is designed as an orally bioavailable pan-KRAS inhibitor, targeting multiple KRAS mutant variants — a broader approach than the allele-specific inhibitors currently approved. SYNB011128 is a preclinical-stage bispecific peptide-drug conjugate targeting both EGFR and carbonic anhydrase IX, a protein associated with hypoxic tumour microenvironments.

Syneron's strategic relationship with AstraZeneca predates the Series B. The platform drew external validation through a March 2025 research collaboration and licensing agreement with AstraZeneca, structured around access to Synova for the discovery of macrocyclic peptide candidates in chronic diseases. That deal carries potential milestone payments of up to $3.4 billion, with tiered royalties on any commercialised products, as well as an equity investment from AstraZeneca. The UK giant's continued participation in the Series B round reflects the ongoing nature of that arrangement.

Novartis commits up to $1.8 billion to Unnatural Products

While Syneron represents the China-based macrocycle story, Unnatural Products (UNP) of Santa Cruz, California, exemplifies the Western platform model. UNP secured a partnership with Novartis in a deal that could garner up to $1.7 billion in biobucks. Novartis is paying $100 million in upfront and preclinical milestone payments to work with the California biotech on efforts to develop next-generation cardiovascular disease therapeutics, gaining access to UNP's AI-guided platform, a discovery engine designed to quickly create potent and selective macrocycles that can be delivered both orally and via injection.

Novartis will be in charge of all IND-enabling studies and any subsequent clinical development, manufacturing and commercialisation of potential drugs, while UNP could bank up to $1.7 billion in development, regulatory and commercial milestone payments, plus tiered royalties on potential annual sales.

The Novartis transaction is notable because it follows a near-identical structural logic to UNP's earlier collaborations. The Novartis collaboration came seven months after UNP inked an up-to-$1.5 billion-plus collaboration with argenx to discover and develop synthetic oral macrocyclic peptide drugs targeting multiple immunology targets. In 2024, Merck agreed to partner with UNP on designing and developing macrocyclic candidates against an oncology therapeutic target, agreeing to pay an undisclosed upfront payment plus up to approximately $220 million in payments tied to achieving milestones.

In March 2026, UNP closed a $45 million Series B financing, having previously announced a licensing agreement with Novartis to develop macrocyclic peptide therapeutics for historically undruggable cardiovascular targets, including up to $100 million upfront and up to $1.7 billion in total potential milestones. The company is also advancing a pipeline of macrocyclic peptide therapeutics for the treatment of cardiometabolic, inflammatory and immunological diseases.

Why the modality is attracting platform-level investment

Several structural features are converging to make macrocyclic peptides attractive to large pharmaceutical investors at this moment.

Oral delivery potential. Linear peptides are almost universally injectable, which constrains their commercial addressable market. Macrocyclic peptides designed to selectively bind to complex intracellular pathways offer potential for cell permeability and oral delivery — an innovation that could transform the treatment landscape for diseases currently addressed by costly injectable therapies.

AI-accelerated discovery. Both Syneron and UNP cite AI-guided platforms as the core enabler of their programmes. Synova integrates high-throughput screening using next-generation artificial intelligence and data science tools to discover optimal peptide candidates in ways that can significantly outpace current time-to-market schedules.

Patent cliff pressure. The looming patent cliff is a major driver of M&A and platform licensing activity, with over $230 billion in biopharma revenue at risk due to loss of exclusivity over the coming years. Macrocyclic peptide platforms, with broad claims across a novel structural space, represent one mechanism for building defensible future pipelines.

GPCR and incretin receptor interest. The GLP-1 receptor — itself a class B GPCR — has demonstrated that peptide-based receptor agonism can produce blockbuster medicines. GPCRs have become a major focus for drug discovery, particularly with the advent of drugs targeting the GLP-1 receptor and other incretin receptors, which are relevant in the treatment of metabolic diseases. Macrocyclic peptides are being evaluated as a route to GPCR agonists with improved oral bioavailability.

Implications for the broader peptide research landscape

The investment wave sits at a considerable distance from the compounding-pharmacy and research-use debates that dominate near-term regulatory discourse in the United States and United Kingdom. Macrocyclic peptide platforms are firmly in formal drug development, progressing through IND-enabling studies and aimed at NDA or BLA submissions years hence.

However, the surge is relevant to research-procurement professionals in two respects. First, the modality is generating published preclinical data — primarily from AACR and ASH meetings — that may become reference material for academic labs designing peptide-mediated target engagement studies. Second, platform validation by AstraZeneca, Novartis, argenx and Merck reinforces the credibility of macrocyclic chemistry as a mainstream research area, which in turn drives demand for synthetic peptide libraries, HPLC-grade reference standards and high-purity building blocks.

Syneron plans to use its Series B funds to advance its diversified innovative pipeline into clinical development, specifically targeting IND-enabling studies, with formal IND filings anticipated with both the NMPA in China and the FDA in the United States. Clinical entry for either SYNB021225 or SYNB011128 would represent the first publicly disclosed clinical programme for an AI-designed macrocyclic peptide from a China-based biotech, a milestone the industry will watch closely.

The overall picture for 2026 is of a peptide sector bifurcating in its strategic profile: near-term attention on US compounding rules and the July PCAC review for legacy research peptides, and longer-term capital concentration in AI-enabled macrocyclic platforms targeting biology that conventional drug classes cannot reach.

This briefing is produced by BSR Intelligence for research-procurement professionals at UK and international laboratories. It does not constitute investment advice or regulatory guidance.